AQST
Price
$5.42
Change
+$0.36 (+7.11%)
Updated
Sep 5 closing price
Capitalization
655.68M
65 days until earnings call
NBIX
Price
$144.10
Change
+$3.70 (+2.64%)
Updated
Sep 5 closing price
Capitalization
14.29B
59 days until earnings call
Interact to see
Advertisement

AQST vs NBIX

Header iconAQST vs NBIX Comparison
Open Charts AQST vs NBIXBanner chart's image
Aquestive Therapeutics
Price$5.42
Change+$0.36 (+7.11%)
Volume$6.08M
Capitalization655.68M
Neurocrine Biosciences
Price$144.10
Change+$3.70 (+2.64%)
Volume$1.23M
Capitalization14.29B
AQST vs NBIX Comparison Chart in %
Loading...
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AQST vs. NBIX commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a StrongBuy and NBIX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (AQST: $5.42 vs. NBIX: $144.10)
Brand notoriety: AQST and NBIX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AQST: 366% vs. NBIX: 137%
Market capitalization -- AQST: $655.68M vs. NBIX: $14.29B
AQST [@Pharmaceuticals: Generic] is valued at $655.68M. NBIX’s [@Pharmaceuticals: Generic] market capitalization is $14.29B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AQST’s FA Score shows that 0 FA rating(s) are green whileNBIX’s FA Score has 1 green FA rating(s).

  • AQST’s FA Score: 0 green, 5 red.
  • NBIX’s FA Score: 1 green, 4 red.
According to our system of comparison, NBIX is a better buy in the long-term than AQST.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AQST’s TA Score shows that 6 TA indicator(s) are bullish while NBIX’s TA Score has 5 bullish TA indicator(s).

  • AQST’s TA Score: 6 bullish, 5 bearish.
  • NBIX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both AQST and NBIX are a good buy in the short-term.

Price Growth

AQST (@Pharmaceuticals: Generic) experienced а +43.77% price change this week, while NBIX (@Pharmaceuticals: Generic) price change was +3.22% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

AQST is expected to report earnings on Nov 10, 2025.

NBIX is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($14.3B) has a higher market cap than AQST($656M). AQST YTD gains are higher at: 52.247 vs. NBIX (5.568). NBIX has higher annual earnings (EBITDA): 557M vs. AQST (-47.5M). NBIX has more cash in the bank: 976M vs. AQST (60.5M). AQST has less debt than NBIX: AQST (40.3M) vs NBIX (439M). NBIX has higher revenues than AQST: NBIX (2.51B) vs AQST (44.1M).
AQSTNBIXAQST / NBIX
Capitalization656M14.3B5%
EBITDA-47.5M557M-9%
Gain YTD52.2475.568938%
P/E RatioN/A42.63-
Revenue44.1M2.51B2%
Total Cash60.5M976M6%
Total Debt40.3M439M9%
FUNDAMENTALS RATINGS
AQST vs NBIX: Fundamental Ratings
AQST
NBIX
OUTLOOK RATING
1..100
2817
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
10068
SMR RATING
1..100
10059
PRICE GROWTH RATING
1..100
3746
P/E GROWTH RATING
1..100
10032
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AQST's Valuation (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for NBIX (76) in the Biotechnology industry. This means that AQST’s stock grew somewhat faster than NBIX’s over the last 12 months.

NBIX's Profit vs Risk Rating (68) in the Biotechnology industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew similarly to AQST’s over the last 12 months.

NBIX's SMR Rating (59) in the Biotechnology industry is somewhat better than the same rating for AQST (100) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew somewhat faster than AQST’s over the last 12 months.

AQST's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as NBIX (46) in the Biotechnology industry. This means that AQST’s stock grew similarly to NBIX’s over the last 12 months.

NBIX's P/E Growth Rating (32) in the Biotechnology industry is significantly better than the same rating for AQST (100) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew significantly faster than AQST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AQSTNBIX
RSI
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
53%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
54%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
70%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
72%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
71%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
71%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 27 days ago
59%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
64%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARIIX10.900.09
+0.83%
AB Global Real Estate Investment II I
RYAHX139.121.01
+0.73%
Rydex Mid-Cap 1.5x Strategy A
AIEAX18.470.05
+0.27%
American Beacon International Eq A
JNVMX18.71N/A
N/A
JPMorgan Developed International ValueR6
ISTNX88.82N/A
N/A
Macquarie Science and Technology R6

AQST and

Correlation & Price change

A.I.dvisor tells us that AQST and ESPR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AQST and ESPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
+7.11%
ESPR - AQST
32%
Poorly correlated
+5.93%
NBIX - AQST
30%
Poorly correlated
+2.64%
HROW - AQST
30%
Poorly correlated
+2.18%
SCYX - AQST
30%
Poorly correlated
+2.43%
TLRY - AQST
29%
Poorly correlated
+3.48%
More